We have assembled a portfolio of gene therapy candidates in partnership with leading scientific institutions and have built a team with extensive experience in the biotechnology commercialization and gene therapy space. Our team will pursue new innovations in vector design and delivery to optimize our investigational gene therapy product candidates for safety, potency, durability, and clinical response. We plan on building integrated internal development capabilities from product development through commercialization and focus on accelerating the pace of product development in the clinic. In addition, as part of our ongoing business strategy, we continue to explore potential opportunities to acquire or license new product candidates as well as opportunities for partnership or collaboration on our existing products in development.

We have a highly experienced team managing our key cell therapy and gene therapy platform. That platform uses a gene therapy approach to introduce a human gene into the body. That gene is our patent-protected secreted form of Klotho, s-KL. The s-KL gene when introduced into the body produces Klotho, a therapeutic protein to treat neurodegenerative diseases and other age-related disorders.

This innovative technology platform technology was in-licensed by Klotho Neurosciences from the Autonomous University of Barcelona (UAB) on an exclusive worldwide basis. We, therefore, plan to rigorously exploit the therapeutic potential of the human α-Klotho gene in developing treatments for neurodegenerative diseases, such as ALS (our lead product development target), Alzheimer’s and Parkinson’s diseases, as well as other age-related disorders and achieving healthy longevity. It is our belief that there is limited competition investigating such therapeutic approaches to these targets due to our intellectual property position and technology know-how.